Ramon Flick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ramon Flick has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexander N. Freiberg
Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA
2 shared publications - Alexander Plyusnin
Department of Virology, University of Helsinki, Finland
2 shared publications - Anna Katz
Research Programs Unit, Infection Biology Research Program, Department of Virology, Haartman Institute, PO Box 21, University of Helsinki, 00014 Helsinki, Finland
2 shared publications - Antti Vaheri
Department of Virology, Medicum, University of Helsinki, 00290 Helsinki, Finland
2 shared publications - Liisa Holm
Organismal and Evolutionary Biology Research Programme, Faculty of Biological and Environmental Sciences, and Institute of Biotechnology, Helsinki Institute of Life Sciences, University of Helsinki, Finland
2 shared publications - Vera Backström
Research Programs Unit, Infection Biology Research Program, Department of Virology, Haartman Institute, P.O. Box 21, University of Helsinki, 00014 Helsinki, Finland
2 shared publications
Latest Publications
- 7 September 2012
- Published by Wiley in Zoonoses and Public Health
- Vol. 59 (s2) , 142-150
Virus‐Like Particle‐Based Countermeasures Against Rift Valley Fever Virus
Rift Valley fever virus (RVFV) is an arbovirus that causes significant morbidity and mortality in both humans and livestock. With increased world travel and the threat of bioterrorism, there is a real risk of RVFV spreading to naïve geographical areas (Trans. R. Soc. Trop. Med. Hyg., 73, 1979, 618; MMWR Morb. Mortal. Wkly Rep., 49, 2000, 905). The introduction of RVFV would cause critical public health, agricultural and economic damage. Despite the clear need for an efficacious vaccine, there are no United States (US) Food and Drug Administration or US Department of Agriculture approved vaccines against RVFV. To address this need, a virus-like particle (VLP)-based vaccine candidate was developed. First, a non-replicating chimeric RVF VLP vaccine candidate was generated that protected mice and rats against a lethal RVFV challenge. This was followed by the development and optimization of conditions for production of RVF VLPs in insect and mammalian cells. Immunological studies demonstrated that VLP-based vaccine candidates elicit both humoral and cellular immune responses. Subsequent challenge studies using a lethal wild-type RVFV strain under high-containment conditions showed that RVF VLP vaccine candidates can completely protect mice and rats.
- 7 September 2012
- Published by Wiley in Zoonoses and Public Health
- Vol. 59 (s2) , 142-150
Virus‐Like Particle‐Based Countermeasures Against Rift Valley Fever Virus
Rift Valley fever virus (RVFV) is an arbovirus that causes significant morbidity and mortality in both humans and livestock. With increased world travel and the threat of bioterrorism, there is a real risk of RVFV spreading to naïve geographical areas (Trans. R. Soc. Trop. Med. Hyg., 73, 1979, 618; MMWR Morb. Mortal. Wkly Rep., 49, 2000, 905). The introduction of RVFV would cause critical public health, agricultural and economic damage. Despite the clear need for an efficacious vaccine, there are no United States (US) Food and Drug Administration or US Department of Agriculture approved vaccines against RVFV. To address this need, a virus-like particle (VLP)-based vaccine candidate was developed. First, a non-replicating chimeric RVF VLP vaccine candidate was generated that protected mice and rats against a lethal RVFV challenge. This was followed by the development and optimization of conditions for production of RVF VLPs in insect and mammalian cells. Immunological studies demonstrated that VLP-based vaccine candidates elicit both humoral and cellular immune responses. Subsequent challenge studies using a lethal wild-type RVFV strain under high-containment conditions showed that RVF VLP vaccine candidates can completely protect mice and rats.
- 17 April 2012
- Published by Elsevier in Virus Research
- Vol. 167 (1) , 118-123
Mutational analysis of positively charged amino acid residues of Uukuniemi phlebovirus nucleocapsid protein
- 17 April 2012
- Published by Elsevier in Virus Research
- Vol. 167 (1) , 118-123
Mutational analysis of positively charged amino acid residues of Uukuniemi phlebovirus nucleocapsid protein
- Open Access
- 10 August 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 187
Oligomerization of Uukuniemi virus nucleocapsid protein
Uukuniemi virus (UUKV) belongs to the Phlebovirus genus in the family Bunyaviridae. As a non-pathogenic virus for humans UUKV has served as a safe model bunyavirus in a number of studies addressing fundamental questions such as organization and regulation of viral genes, genome replication, structure and assembly. The present study is focused on the oligomerization of the UUKV nucleocapsid (N) protein, which plays an important role in several steps of virus replication. The aim was to locate the domains involved in the N protein oligomerization and study the process in detail. A set of experiments concentrating on the N- and C-termini of the protein was performed, first by completely or partially deleting putative N-N-interaction domains and then by introducing point mutations of amino acid residues. Mutagenesis strategy was based on the computer modeling of secondary and tertiary structure of the N protein. The N protein mutants were studied in chemical cross-linking, immunofluorescence, mammalian two-hybrid, minigenome, and virus-like particle-forming assays. The data showed that the oligomerization ability of UUKV-N protein depends on the presence of intact α-helices on both termini of the N protein molecule and that a specific structure in the N-terminal region plays a crucial role in the N-N interaction(s). This structure is formed by two α-helices, rich in amino acid residues with aromatic (W7, F10, W19, F27, F31) or long aliphatic (I14, I24) side chains. Furthermore, some of the N-terminal mutations (e.g. I14A, I24A, F31A) affected the N protein functionality both in mammalian two-hybrid and minigenome assays. UUKV-N protein has ability to form oligomers in chemical cross-linking and mammalian two-hybrid assays. In mutational analysis, some of the introduced single-point mutations abolished the N protein functionality both in mammalian two-hybrid and minigenome assays, suggesting that especially the N-terminal region of the UUKV-N protein is essential for the N-N interaction.
- 10 August 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 187
Open AccessOligomerization of Uukuniemi virus nucleocapsid protein
Uukuniemi virus (UUKV) belongs to the Phlebovirus genus in the family Bunyaviridae. As a non-pathogenic virus for humans UUKV has served as a safe model bunyavirus in a number of studies addressing fundamental questions such as organization and regulation of viral genes, genome replication, structure and assembly. The present study is focused on the oligomerization of the UUKV nucleocapsid (N) protein, which plays an important role in several steps of virus replication. The aim was to locate the domains involved in the N protein oligomerization and study the process in detail. A set of experiments concentrating on the N- and C-termini of the protein was performed, first by completely or partially deleting putative N-N-interaction domains and then by introducing point mutations of amino acid residues. Mutagenesis strategy was based on the computer modeling of secondary and tertiary structure of the N protein. The N protein mutants were studied in chemical cross-linking, immunofluorescence, mammalian two-hybrid, minigenome, and virus-like particle-forming assays. The data showed that the oligomerization ability of UUKV-N protein depends on the presence of intact α-helices on both termini of the N protein molecule and that a specific structure in the N-terminal region plays a crucial role in the N-N interaction(s). This structure is formed by two α-helices, rich in amino acid residues with aromatic (W7, F10, W19, F27, F31) or long aliphatic (I14, I24) side chains. Furthermore, some of the N-terminal mutations (e.g. I14A, I24A, F31A) affected the N protein functionality both in mammalian two-hybrid and minigenome assays. UUKV-N protein has ability to form oligomers in chemical cross-linking and mammalian two-hybrid assays. In mutational analysis, some of the introduced single-point mutations abolished the N protein functionality both in mammalian two-hybrid and minigenome assays, suggesting that especially the N-terminal region of the UUKV-N protein is essential for the N-N interaction.
- 1 July 2010
- Published by Taylor & Francis in Human Vaccines
- Vol. 6 (7) , 597-601
Rift Valley fever virus: An unrecognized emerging threat?
Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. As its geographic range continues to spread, it pres...
- 1 July 2010
- Published by Taylor & Francis in Human Vaccines
- Vol. 6 (7) , 597-601
Rift Valley fever virus: An unrecognized emerging threat?
Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. As its geographic range continues to spread, it pres...
- 1 November 2009
- Published by Elsevier in Antiviral Research
- Vol. 84 (2) , 101-118
Reverse genetics technology for Rift Valley fever virus: Current and future applications for the development of therapeutics and vaccines
- 1 November 2009
- Published by Elsevier in Antiviral Research
- Vol. 84 (2) , 101-118
Reverse genetics technology for Rift Valley fever virus: Current and future applications for the development of therapeutics and vaccines
- 1 January 2007
- Published by Springer Nature
- p. 35-44
Molecular Biology of the Crimean-Congo Hemorrhagic Fever Virus
- 1 January 2007
- Published by Springer Nature
- p. 35-44
Molecular Biology of the Crimean-Congo Hemorrhagic Fever Virus